Approval · Notice of Compliance 18962 · 2017
SANDOZ SUMATRIPTAN: Notice of Compliance 18962
Issued February 10, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18962
- Date
- February 10, 2017
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Update to product monograph to be in line with crp
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SANDOZ SUMATRIPTAN | 02263025 | Cancelled Post Market |
| SANDOZ SUMATRIPTAN | 02263033 | Cancelled Post Market |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB